ClinicalTrials.gg
RecruitingNCT07831096Updated Sep 21, 2026

Anterior Suprascapular Versus Interscalene Block for Postoperative Analgesia After Arthroscopic Shoulder Surgery in the Outpatient Setting

An interventional study of Interscalene Nerve Block and Anterior suprascapular nerve block in Postoperative Pain, Acute, sponsored by ASST Sette Laghi. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by ASST Sette Laghi · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2026, registered Sep 2026).
  • Started Jan 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 115 studies in Pain, Postoperative with a site in Italy — 18 open to participants now, 21 under way, none of them phase 3. Pain, Postoperative · Italy.

Planned enrollment
30th of 86
100 · median 79
Started
2026
with 2 others
No phase
63 of 115
12 open now
Primary completion
2027-02
later than 15 of 20 live
Registered
115th of 115
by date

Among the 115 studies in Pain, Postoperative with a site in Italy, this one is the 30th largest by planned enrollment of the 86 interventional ones that give a count, is one of 3 that started in 2026, is one of 63 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 115th registered.

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

18 of the 115 studies in Pain, Postoperative with a site in Italy are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 241 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Pain, Postoperative with a site in Italy, or all of them as a file.
02

Study summary

Shoulder surgery performed in the outpatient setting can be associated with moderate to severe postoperative pain, especially during the first hours after surgery. Regional anesthesia is commonly used to improve postoperative pain control, reduce opioid use, and support early recovery and safe discharge.

The interscalene block (ISB) is widely considered an effective regional anesthesia technique for shoulder surgery, but it may be associated with adverse effects such as diaphragmatic impairment, dyspnea, hoarseness, Horner syndrome, and prolonged upper limb motor block. The anterior suprascapular nerve block (SSNB-A) is a more selective regional anesthesia technique that may provide comparable postoperative analgesia with fewer block-related adverse effects.

This prospective, randomized, single-blind, noninferiority trial compares SSNB-A with ISB in adult patients undergoing unilateral shoulder surgery in the outpatient setting. All participants receive general anesthesia and the same multimodal analgesic strategy. The primary objective is to determine whether SSNB-A is noninferior to ISB for postoperative pain control, assessed using the Numeric Rating Scale (NRS). Secondary outcomes include quality of recovery measured with the QoR-15 questionnaire, block-related adverse events, sensory and motor block characteristics, and the need for rescue analgesic medication.

Read the detailed description

Shoulder surgery in the outpatient setting requires an anesthetic and analgesic strategy that provides effective postoperative pain control while allowing early recovery and safe discharge. Unilateral shoulder procedures may be associated with moderate to severe postoperative pain, particularly during the first 24 to 48 hours after surgery. In this context, regional anesthesia is an important component of perioperative pain management because it can reduce postoperative pain, decrease the need for opioid analgesics, limit postoperative nausea and vomiting, and facilitate early rehabilitation and recovery.

The interscalene brachial plexus block (ISB) is commonly used for postoperative analgesia after shoulder surgery and is considered one of the most effective regional anesthesia techniques for this indication. However, ISB may be associated with block-related adverse effects, including variable phrenic nerve involvement with diaphragmatic impairment, dyspnea, Horner syndrome, hoarseness, and prolonged motor block of the upper limb. These effects may be particularly relevant in the outpatient setting, where delayed discharge, unplanned admission, or reduced quality of recovery may occur if adverse effects persist after surgery.

The anterior suprascapular nerve block (SSNB-A) has been proposed as a regional anesthesia technique for shoulder surgery that may provide effective analgesia while potentially reducing some of the adverse effects associated with ISB. The suprascapular nerve contributes substantially to the sensory innervation of the shoulder. The anterior approach targets the nerve in the supraclavicular region and may also allow local anesthetic spread toward relevant components of the superior trunk region involved in shoulder innervation. Available evidence suggests that SSNB-A may provide postoperative analgesia comparable to ISB in selected shoulder procedures, with a potentially more favorable side-effect profile.

This study is a prospective, monocentric, randomized, single-blind, noninferiority trial comparing SSNB-A with ISB for postoperative analgesia in adult patients undergoing unilateral shoulder surgery in the outpatient setting. Participants are randomized to receive either an ultrasound-guided interscalene block or an ultrasound-guided anterior suprascapular nerve block before surgery. Randomization is performed shortly before the procedure using block randomization in order to ensure balanced allocation between the two study groups.

Eligible participants are adult patients scheduled for unilateral shoulder surgery in the outpatient setting under general anesthesia. Surgical procedures may include long head of biceps tenotomy, biceps anchor repair, Bankart procedure, rotator cuff repair with or without biological membrane augmentation, subacromial decompression, acromioplasty, and acromioclavicular stabilization. Participants are screened according to predefined inclusion and exclusion criteria. Exclusion criteria include contraindications to regional anesthesia, allergy to local anesthetics or study analgesic drugs, known neuropathy or sensory or motor deficits in the surgical area or block territory, severe obesity, severe chronic obstructive pulmonary disease, pregnancy, known phrenic nerve paralysis with diaphragmatic paralysis, chronic opioid use, severe chronic pain, and inability or unwillingness to follow the postoperative analgesic protocol.

Both regional anesthesia techniques are routinely used at the study center and are performed by anesthesiologists experienced in ultrasound-guided upper limb nerve blocks. In the ISB group, the block is performed with the patient in the supine or semi-sitting position, with the head turned away from the surgical side. The brachial plexus is identified between the anterior and middle scalene muscles at the level of the cricoid cartilage using a linear ultrasound probe. An echogenic 21-gauge needle is advanced with an in-plane technique toward the space between the C5 and C6 nerve roots. After negative aspiration, 10 mL of ropivacaine 0.5% is injected in divided boluses to obtain adequate local anesthetic spread.

In the SSNB-A group, the block is performed with the patient in the supine or semi-sitting position, with the head turned away from the surgical side. The superior trunk of the brachial plexus is identified using a linear ultrasound probe, and the suprascapular nerve is visualized in the supraclavicular fossa as it separates from the superior trunk and courses beneath the inferior belly of the omohyoid muscle. An echogenic 21-gauge needle is advanced with an in-plane technique toward the suprascapular nerve. After negative aspiration, 10 mL of ropivacaine 0.5% is injected in divided boluses to obtain adequate spread around the nerve.

All participants undergo general anesthesia according to the study protocol. Intraoperative monitoring includes oxygen saturation, heart rate, noninvasive blood pressure, 5-lead electrocardiography, bispectral index monitoring, end-tidal carbon dioxide, and body temperature. Dexamethasone 0.15 mg/kg is administered intravenously before surgical incision. General anesthesia is maintained with inhaled anesthetics and opioids. Before the end of surgery, paracetamol 15 mg/kg and ondansetron 0.1 mg/kg are administered according to the protocol. After emergence from anesthesia, participants are observed in the post-anesthesia care unit.

Postoperative analgesia is standardized in both study groups. In the post-anesthesia care unit, if postoperative pain is rated as NRS 4 or higher, ketorolac 30 mg intravenously is administered as first-line rescue analgesia. If pain remains uncontrolled after 30 minutes, tramadol 1 mg/kg intravenously is administered as second-line rescue analgesia. Participants are discharged from the post-anesthesia care unit to the day surgery ward when Aldrete discharge criteria are met. During the day surgery stay, participants continue the standardized recovery pathway, including monitoring of vital signs, pain control, mobilization, oral intake, hydration, and spontaneous urination. Additional postoperative analgesia during the ward stay includes oral paracetamol and ibuprofen as rescue therapy according to the study protocol.

At discharge, participants receive instructions for the postoperative multimodal analgesic regimen and the data collection forms. Post-discharge follow-up is performed by telephone at predefined time points in order to assess pain control, adherence to the analgesic regimen, recovery, adverse events, and outcome measures. Quality of recovery is assessed using the QoR-15 questionnaire during follow-up. Postoperative pain is assessed using the Numeric Rating Scale at predefined time points after surgery.

The primary objective of the study is to determine whether SSNB-A is noninferior to ISB in terms of postoperative pain control after shoulder surgery in the outpatient setting. The primary endpoint is postoperative pain measured by the Numeric Rating Scale, with the main analysis focused on the NRS score at 6 hours after surgery. The noninferiority margin is defined as 1.1 points on the 0-to-10 NRS scale.

Secondary objectives include comparison of block-related adverse events, including dyspnea, oxygen desaturation, hoarseness, Horner syndrome, pneumothorax, and neurologic complications; assessment of quality of recovery using the QoR-15 questionnaire at discharge and during postoperative follow-up up to postoperative day 5 and at 30 days; comparison of sensory and motor block characteristics in the relevant dermatomes and myotomes; and comparison of rescue analgesic use within a standardized multimodal analgesic protocol.

Baseline demographic and clinical data are collected before the anesthetic procedures, including age, sex, weight, height, ASA physical status, previous surgery, allergies, current medications, and relevant medical history. Intraoperative and postoperative data are collected according to the study protocol. Participants and postoperative outcome assessors are blinded to group allocation, while the anesthesiologist performing the block is not blinded. Statistical analyses are planned before completion of data collection and are performed by an investigator blinded to treatment allocation.

The planned sample size is 100 participants. The sample size calculation is based on the primary noninferiority analysis of postoperative NRS pain scores, assuming a noninferiority margin of 1.1, an estimated standard deviation of 2, a one-sided type I error rate of 5%, and a type II error rate below 20%. The sample size is increased to account for protocol deviations and exclusions, as the primary analysis is planned according to a per-protocol approach.

The study is conducted in accordance with the principles of Good Clinical Practice, the Declaration of Helsinki, and applicable national and international regulations regarding personal data protection. Written informed consent is obtained from all participants before enrollment.

03

Conditions studied

  • Postoperative Pain, Acute

Browse trials for

Keywords

  • Shoulder surgery
  • Interscalene block
  • Anterior suprascapular nerve block
  • Regional Anesthesia
  • Outpatient Surgery
  • Postoperative analgesia
  • Quality of recovery
  • Numeric Rating Scale
  • Multimodal Analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years.
  • I, II, or III.
  • Scheduled for unilateral shoulder orthopedic surgery in the outpatient/day surgery setting under general anesthesia.
  • Surgical procedures may include long head of biceps tenotomy, biceps anchor repair, Bankart procedure, rotator cuff repair with or without biological membrane augmentation, subacromial decompression, acromioplasty, or acromioclavicular stabilization.
  • Ability to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • to regional anesthesia, including allergy to local anesthetics, infection at the injection site, bleeding diathesis, or other contraindications according to applicable clinical practice recommendations.
  • Allergy to paracetamol or to any drug used in the multimodal rescue analgesic strategy.
  • Known neuropathy or sensory/motor deficit in the surgical area or in the territory of innervation of the study blocks.
  • History of psychiatric or behavioral disorders that may interfere with study participation or outcome assessment.
  • Severe obesity, defined as (BMI) > 40 kg/m2.
  • Severe , GOLD stage III-IV.
  • Pregnancy.
  • Known phrenic nerve palsy associated with diaphragmatic paralysis.
  • Chronic opioid use during the previous 3 months.
  • Severe chronic pain during the previous 3 months, defined as NRS > 4.
  • Non-adherence to the postoperative analgesic protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Interscalene block

    Participants randomized to this group receive an ultrasound-guided interscalene brachial plexus block before shoulder surgery, followed by standardized general anesthesia and the same multimodal postoperative analgesic protocol used in both study groups.

    Procedure: Interscalene Nerve Block · Drug: Ropivacaine

  • Experimental
    Anterior Suprascapular Nerve Block

    Participants randomized to this group receive an ultrasound-guided anterior suprascapular nerve block before shoulder surgery, followed by standardized general anesthesia and the same multimodal postoperative analgesic protocol used in both study groups.

    Procedure: Anterior suprascapular nerve block · Drug: Ropivacaine

Interventions

  • ProcedureInterscalene Nerve Block

    Participants receive an ultrasound-guided interscalene brachial plexus block before shoulder surgery using 10 mL of ropivacaina 0,5%, followed bu standardized general anesthesia and postoperative multimodal analgesia

    Also known as: Ultrasound-guided interscalene block, ISB

  • ProcedureAnterior suprascapular nerve block

    Participants receive an ultrasound-guided anterior suprascapular nerve block before shoulder surgery using 10 mL of ropivacaine 0,5%, followed by standardized general anesthesia and postoperative multimodal analgesia.

    Also known as: SSNB-A, Ultrasound-guided anterior suprascapular nerve block

  • Ropivacaine 0.5% is used as the local anesthetic for the assigned ultrasound-guided regional anesthesia procedure. Participants receive 10 mL of ropivacaine 0.5% either for interscalene brachial plexus block or for anterior suprascapular nerve block, according to randomized group allocation. The same drug concentration and volume are used in both study groups.

    Also known as: Ropivacaine 0.5%

06

What researchers measure

Primary outcomes

  1. Postoperative pain intensity at 6 hours after surgery

    Postoperative pain intensity assessed using the Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. The primary analysis compares NRS pain scores between the anterior suprascapular nerve block group and the interscalene block group to assess noninferiority.

    Time frame: 6 hours after surgery

Secondary outcomes

  1. Postoperative Pain Intensity at Other Predefined Postoperative Time Points

    Postoperative pain intensity assessed using the Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain, at predefined postoperative time points other than the primary 6-hour endpoint

    Time frame: At post-anesthesia care unit arrival and at 12, 18, 24, 36, 48, and 72 hours after surgery

  2. Quality of Recovery

    Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15). The QoR-15 is a patient-reported outcome measure evaluating postoperative recovery across multiple domains, including pain, physical comfort, physical independence, psychological support, and emotional state. Higher scores indicate better quality of recovery. Scores will be compared between the two study groups at predefined postoperative time points.

    Time frame: On postoperative day 0, postoperative day 1, postoperative day 2, postoperative day 3, and postoperative day 5

  3. Incidence of Block-Related Adverse Events

    Incidence of adverse events potentially related to the regional anesthesia technique, including dyspnea, oxygen desaturation, hoarseness, Horner syndrome, pneumothorax, and neurologic complications. The incidence of these events will be compared between the anterior suprascapular nerve block group and the interscalene block group.

    Time frame: From block performance through postoperative day 0

  4. Rescue Analgesic Consumption

    Use of rescue analgesic medication for uncontrolled postoperative pain within the standardized multimodal analgesic protocol. During the postoperative hospital stay, first-line rescue analgesia consists of nonsteroidal anti-inflammatory drugs and second-line rescue analgesia consists of opioid analgesics. After discharge, rescue analgesic use includes dexibuprofen 400 mg as first-line rescue medication and tapentadol 50 mg as second-line rescue medication. For each rescue analgesic administration or intake, the timing and the NRS pain score at the time of use will be recorded. Rescue analgesic consumption will be compared between the anterior suprascapular nerve block group and the interscalene block group.

    Time frame: From post-anesthesia care unit arrival through postoperative day 5

  5. Sensory and Motor Block Characteristics

    Sensory and motor block characteristics assessed after regional anesthesia in the relevant nerve territories. Sensory and motor function will be evaluated in C5, C6, C7, C8, T1, and superior trunk territory using a 3-point scale, where 2 indicates normal sensation or motor function, 1 indicates reduced sensation or motor function, and 0 indicates absent sensation or motor function. The extent, onset, and persistence of sensory and motor block will be compared between the anterior suprascapular nerve block group and the interscalene block group.

    Time frame: At 30 minutes after block performance, at post-anesthesia care unit arrival, and 6 hours after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dogan AT, Cosarcan SK, Gurkan Y, Koyuncu O, Ercelen O, Demirhan M. Comparison of anterior suprascapular nerve block versus interscalane nerve block in terms of diaphragm paralysis in arthroscopic shoulder surgery: a prospective randomized clinical study. Acta Orthop Traumatol Turc. 2022 Nov;56(6):389-394. doi: 10.5152/j.aott.2022.22044. PubMed 36567542 ↗
  • Lim YC, Koo ZK, Ho VW, Chang SS, Manohara S, Tong QJ. Randomized, controlled trial comparing respiratory and analgesic effects of interscalene, anterior suprascapular, and posterior suprascapular nerve blocks for arthroscopic shoulder surgery. Korean J Anesthesiol. 2020 Oct;73(5):408-416. doi: 10.4097/kja.20141. Epub 2020 Jul 16. PubMed 32668833 ↗
  • White L, Reardon D, Davis K, Velli G, Bright M. Anterior suprascapular nerve block versus interscalene brachial plexus block for arthroscopic shoulder surgery: a systematic review and meta-analysis of randomized controlled trials. J Anesth. 2022 Feb;36(1):17-25. doi: 10.1007/s00540-021-03000-z. Epub 2021 Sep 17. PubMed 34533639 ↗
  • Abdallah FW, Wijeysundera DN, Laupacis A, Brull R, Mocon A, Hussain N, Thorpe KE, Chan VWS. Subomohyoid Anterior Suprascapular Block versus Interscalene Block for Arthroscopic Shoulder Surgery: A Multicenter Randomized Trial. Anesthesiology. 2020 Apr;132(4):839-853. doi: 10.1097/ALN.0000000000003132. PubMed 32044802 ↗

Individual participant data

Plan to share: Undecided — Individual participant data will not be shared. Study results may be published in aggregate and fully anonymized form. Information allowing participant identification will remain confidential and will not be disclosed outside the study center, except for authorized monitoring or regulatory purposes as allowed by applicable laws and consent procedures.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.

Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 13 months is above that.

Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 21, 2026
StartActual
Jan 16, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07831096
Lead sponsor
ASST Sette Laghi
Responsible party
Giorgio Rossoni (MD, Ospedale di Circolo - Fondazione Macchi) — Principal investigator
First posted
Sep 21, 2026
Start date
Jan 16, 2026
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Giorgio Rossoni, MD
Contact
giorgio.rossoni@asst-settelaghi.it
0039 0332393447
Anna Marcato Anna Marcato, MD
Contact
anna.marcato@asst-settelaghi.it
0039 0332393447

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion